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Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI) antidepressant, is among the most prescribed
pharmaceutical active substances worldwide. This study aimed to assess its accumulation and metab-
olization in the mussel Mytillus galloprovincialis, considered an excellent sentinel species for traditional
and emerging pollutants. Mussels were collected from Ria Formosa Lagoon, Portugal, and exposed to a
nominal concentration of ﬂuoxetine (75 ng L1) for 15 days. Approximately 1 g of whole mussel soft
tissues was extracted with acetonitrile:formic acid, loaded into an Oasis MCX cartridge, and ﬂuoxetine
analysed by liquid chromatography with tandem mass spectrometry (LC-MSn). After 3 days of exposure,
ﬂuoxetine was accumulated in 70% of the samples, with a mean of 2.53 ng g1 dry weight (d.w.) and
norﬂuoxetine was only detected in one sample (10%), at 3.06 ng g1 d.w. After 7 days of exposure, the
accumulation of ﬂuoxetine and norﬂuoxetine increased up to 80 and 50% respectively, and their mean
accumulated levels in mussel tissues were up to 4.43 and 2.85 ng g1 d.w., respectively. By the end of the
exposure period (15 days), both compounds were detected in 100% of the samples (mean of 9.31 and
11.65 ng g1 d.w., respectively). Statistical analysis revealed signiﬁcant accumulation differences between
the 3rd and 15th day of exposure for ﬂuoxetine, and between the 3rd and 7th against the 15th day of
exposure for norﬂuoxetine. These results suggest that the ﬂuoxetine accumulated in mussel tissues is
likely to be metabolised into norﬂuoxetine with the increase of the time of exposure, giving evidence
that at these realistic environmental concentrations, toxic effects of ﬂuoxetine in mussel tissues may
occur.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
According to the latest report of 2011 of the Organisation for
Economic Co-Operation and Development (OECD), the consump-
tion of antidepressants increased more than 60% over the past
decade (Silva et al., 2012). Selective serotonin re-uptake inhibitors
(SSRIs), widely marketed since themid-1980s (Schultz and Furlong,
2008), include ﬂuoxetine that is among the most prescribed phar-
maceutical active substance at national level and worldwide.
Fluoxetine, as the other SSRIs, is primarily prescribed to patientse by Eddy Y. Zeng.
.diagnosed with clinical depression, obsessive-compulsive disorder,
panic disorder, social phobia, and attention-deﬁcit disorder
(Schultz and Furlong, 2008). In mammals, following oral ingestion,
ﬂuoxetine is metabolized and the primary metabolite formed is N-
desmethyl product (norﬂuoxetine) which is more potent than the
parent compound (Silva et al., 2012).
One of the main inputs of pharmaceutical compounds to natural
waters is from wastewater treatment plants (WWTPs) (Silva et al.,
2012). The annual rate of discharge of pharmaceuticals from
municipal WWTPs may reach kilogram levels (Paterson and
Metcalfe, 2008). Furthermore, ﬂuoxetine concentrations ranging
from 0.41 to 141 ng L1 were already reported in surface waters
from Canada, Spain and USA (Silva et al., 2012). Under chronic
exposure conditions, there is potential for pharmaceuticals to
accumulate in ﬁsh and in other aquatic organisms (Paterson and
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ﬂuoxetine was reported to be accumulated in Elliptio spp. mussels
from Crabtree Creek, USA, near a WWTP efﬂuent channel and the
downstream sites (Bringolf et al., 2010). Along with its main
metabolite, norﬂuoxetine, ﬂuoxetine is undoubtedly the SSRI most
investigated, both in the aquatic compartments and in biota (Silva
et al., 2012) and was reported as the most toxic (Brooks et al.,
2003), at levels of at least one order of magnitude lower when
compared with the other SSRIs (Silva et al., 2015).
The phylogenetically ancient and highly conserved neurotrans-
mitter and neurohormone serotonin has been found in vertebrates
and invertebrates, although its speciﬁc physiological role and mode
of action is unknown for many species (Kreke and Dietrich, 2008).
SSRIs affects awide range of aquatic organisms, both vertebrate and
invertebrate, but there is large variation in the sensitivity of or-
ganisms (Sumpter et al., 2014). By increasing the bioavailability of
serotonin, ﬂuoxetine has been described to disrupt the endocrine
systems and many biological functions within invertebrates, such
as reproduction, metabolism, moulting and behaviour (Bossus
et al., 2014; Fong and Ford, 2014; Silva et al., 2015).
The ﬁrst data on ﬂuoxetine and norﬂuoxetine accumulation in
brain, liver, and muscle tissues of different ﬁsh species of efﬂuent-
dominated ecosystems was reported by Brooks et al. (2005). Since
then, some studies reported ﬂuoxetine accumulation in ﬁsh tissues
(Silva et al., 2015) and fewer on refer other aquatic organisms, such
as mussels (Bringolf et al., 2010; Franzellitti et al., 2014; Maruya
et al., 2014).
Fluoxetine, with basic characteristics, binds easily with partic-
ulate materials (Zenker et al., 2014). Thus, dietary routes of ﬂuox-
etine exposure and uptake may be particularly important for
bivalves (Franzellitti et al., 2014). Bivalves are ﬁlter feeders sessile
organisms which draw in water and particles from their sur-
rounding environment (Dodder et al., 2014). There is still a paucity
of data regarding accumulation and metabolization of pharma-
ceuticals, such as ﬂuoxetine, by bivalves and these mechanisms
deserve additional clariﬁcation (Boxall et al., 2012; Franzellitti et al.,
2014; Du et al., 2015). The blue mussel Mytilus galloprovincialis is
generally considered a good bioindicator of environmental quality
and of accumulation of numerous contaminants (Bebianno et al.,
2015). In addition, the exposure to ﬂuoxetine has clearly triggered
several biological responses in this species, namely endocrine
disruption (Gonzalez-Rey and Bebianno, 2013). Therefore, the aim
of this study was to evaluate the uptake, accumulation, and
metabolization of ﬂuoxetine in mussels, M. galloprovincialis,
exposed to an environmental realistic concentration of ﬂuoxetine
(75 ng L1) to complement previous ﬁndings. To our knowledge,
this is the ﬁrst study reporting the metabolization of this phar-
maceutical in bivalves (mussels).
2. Materials and methods
2.1. Standards and chemicals
Reference standards of ﬂuoxetine and norﬂuoxetine hydro-
chloride, the labelled surrogates ﬂuoxetine-d5 hydrochloride, and
norﬂuoxetine-d6 oxalate, all with 98% purity, were purchased
from SigmaeAldrich (St. Louis, MO, USA). Stock and intermediate
solutions were prepared in methanol at 5 mg mL1 and
250 mgmL1, respectively, and stored at20 C, for amaximum of 6
months. Mixed standard working solutions, renewed before each
analytical run, were prepared at 2.5 and 50 ng mL1 in meth-
anol:water (10:90), and used for linearity, accuracy, and repeat-
ability assays. The labelled surrogates were typically prepared to
obtain a ﬁnal concentration of 50 ng mL1.
HPLC-grade acetonitrile and methanol were purchased fromSigmaeAldrich (St. Louis, MO, USA). Water was prepared from a
MilliporeMilli Q system (Bedford,MA, USA). Ammonium hydroxide
and formic acid (98%) were obtained from Merck (Darmstadt,
Germany); hydrochloric acid 37% was from Carlo Erba (Milan, Italy).
2.2. Sample collection and exposure assay
Mussels M. galloprovincialis were collected from a small ﬁshing
and tourist boats harbour in the Ria Formosa Lagoon, Portugal
(3706058.500N 737044.000W). Mussels were transported alive to the
laboratory, the shell was cleaned, and they were acclimatized for
oneweek in aerated natural seawater. Mussels were then separated
and placed in several aquaria (n ¼ 35, 1 mussel L1); four for con-
trols (un-exposed) and three exposed to a nominal concentration of
ﬂuoxetine (75 ng L1). The aquaria were kept at constant temper-
ature (18.6 C ± 1), salinity (33 ± 0.4), pH (8.1 ± 0.2) and oxygen
saturation (>98% ± 2). Mussels were not fed until the end of the
experiment and no mortality occurred. Water was changed every
48 h and ﬂuoxetine concentration re-established (Gonzalez-Rey
and Bebianno, 2013).
At each sampling time (0, 3, 7, and 15 days), mussels (n ¼ 10)
were removed from control and exposed aquaria, freeze-dried and
individually stored at 20 C to determine ﬂuoxetine accumulated
in mussel tissues. Fifteen mussels were removed from each aquaria
and individual shell biometric measured e average shell length
size: 67.60 ± 5.08 mm, width: 37.31 ± 1.77 mm and height
25.48 ± 1.93 (Table S1, Supporting Information) and the Condition
index (CI) quantiﬁed as the ratio shown in equation (1). Data is
presented in Table S1.
CI ð%Þ ¼
h
whole soft tissue w:w:ð Þ  whole body tissue
with shell

w:w:
1i 100
(1)
2.3. Experimental procedure
Each mussel whole soft tissues was grounded into powder, and
±1 g was homogenized and spiked with surrogate standards
(ﬂuoxetine-d5 and norﬂuoxetine-d6) and extracted twice with
10 mL acetonitrile with 0.1% formic acid (Schultz et al., 2010). After
mixing for 5 min, ultrasonication for 15 min, and centrifugation for
10 min at 4 C and 5400g, the supernatant was collected and the
extraction repeated. The supernatants were ﬁnally pooled and
centrifuged for 10 min at 4 C and 20,000g. For solid phase
extraction with Oasis MCX cartridge (150 mg, 6 mL, Waters, Mil-
ford, MA, USA), the extract was loaded into the cartridge previously
conditionedwith 5mLmethanol and 5mL acidiﬁedwater at pH 2.5.
To rinse 2 mL 0.1 N HCl and 2 mL 5% methanol in water were used.
Elution was done with 2 mL methanol following 6 mL 5% ammo-
nium hydroxide in methanol. Finally, the eluate was evaporated to
dryness under a gentle stream of nitrogen, at 40 C, and the dried
extracts were stored at20 C until analysis, that took place in 48 h
maximum.
For liquid chromatography coupled to tandem mass spectrom-
etry (LC-MSn) analysis, the dried eluate was reconstituted in 1 mL
methanol:water (10:90) and microﬁltered through durapore
membrane ﬁlters 0.22 mm (Millipore, Milford, MA, USA). A 20 mL
injection volume was used with a ﬂow rate at 200 mL min1 and a
gradient of (A) water with 0.5% formic acid and (B) methanol with
0.5% formic acid, as presented in Table S2. A chromatographic col-
umn ZORBAX Eclipse XDB-Phenyl (150  3.0 mm; 3.5 mm), main-
tained at 45 C, and guard-column of the same packing material
were used. A hybrid Quadrupole Ion Trap Mass Spectrometer (LCQ
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operated in the positive electrospray ionization (ESI) mode using
selected reaction monitoring (SRM) acquisition. Source and capil-
lary temperatures were set at 0 and 220 C and voltages at 4.5 and
34 V, respectively. Nitrogen was used as nebulizing gas, with a
sheath gas ﬂow of 40 (arbitrary unit) and the auxiliary sweep gas
ﬂow of 10 (arbitrary unit). The collision gas was helium with
normalized collision energy of 30% for ﬂuoxetine and 35% for nor-
ﬂuoxetine. A precursor ion (MS1), and two product ions (MS2 and
MS3) were obtained, as following: ﬂuoxetine (m/z 310 / m/z
148/ m/z 117) e norﬂuoxetine (m/z 296/ m/z 134/ m/z 117).
2.4. Statistical analysis
Complete statistical analyses were performed using GraphPad
Prism (6.01, GraphPad Software, Inc., San Diego, USA). To test
whether the dataset was of Gaussian distribution, D'Agosti-
noePearson normality test was used. Since most of the data set was
not normally distributed, with non-homogeneous variances,
nonparametric tests were applied. For the comparison of ﬂuoxe-
tine, norﬂuoxetine and their sum between different exposure days,
KruskaleWallis test with Dunns post-test were used. The statistical
signiﬁcance level was set to p < 0.05.
3. Results and discussion
3.1. Method validation
The validation of the method (Table 1) was performed to assure
high quality analytical measurements and encompassed different
performance criteria such as sensitivity, linear range, matrix effects,
accuracy, and precision. Linearity was assessed using standard so-
lutions and matrix-matched calibrations by analysing in triplicate
at six concentration levels, between 2.5 and 50 ng mL1, that
correspond, according to the analytical methodology, to the range
of 2.5e50 ng g1, evaluated in matrix-matched linearity. Linearity
was achieved for every compound, in the working standard solu-
tions as conﬁrmed by the correlation coefﬁcient (r2), of 0.9999,
obtained in the calibration curves, for both ﬂuoxetine and nor-
ﬂuoxetine. In matrix-matched solutions, r2 values of 0.9999 were
also obtained.
Matrix effects (ME) equalled the percentage of the matrix-
matched calibration slope (B) divided by the slope of the stan-
dard calibration in solvent (A). Thus, the ratio (B/A 100) was
deﬁned as the absolutematrix effect (ME%). The obtained valuewas
interpreted as follows: a value of 100% denoted an absence of
matrix effects, above 100% signal enhancement and below 100%
signal suppression. Matrix effects for ﬂuoxetine and norﬂuoxetine
were considered negligible, since the values were of 98.59 and
100.00%, respectively.
The method detection limits (MDL) and method quantiﬁcation
limits (MQL) were calculated through the matrix-matched cali-
bration curve as j3.3Sy/xj/b and j10Sy/xj/b, respectively, where b is
the slope and Sy/x the residual standard deviation of the linear
function. Fluoxetine showed MDL and MQL values of 0.69 and
2.09 ng g1 dry weight, respectively, and norﬂuoxetine of 0.81 andTable 1
Performance data obtained for ﬂuoxetine and norﬂuoxetine in mussels spiked samples.
SSRI Matrix matched linearity
(r2)
MDL
(ng g1)
MQL
(ng g1)
ME (%) Recovery
5 ng g1
Fluoxetine 0.9999 0.69 2.09 98.59 90.55
Norﬂuoxetine 0.9999 0.81 2.45 100.00 85.782.45 ng g1 d.w., respectively.
For accuracy and repeatability assays, recoveries were deter-
mined in triplicate, at three different spiking levels, 5, 25 and
50 ng g1, in three different days, and each extract was analysed
three times. For ﬂuoxetine, accuracy varied between 90.55 and
99.76% with intra-day and inter-day repeatability (RSD %) below
0.77 and 10.06%, respectively. For norﬂuoxetine, accuracy varied
between 85.78 and 99.35%, with intra-day and inter-day repeat-
ability below and 2.35 and 1.46%, respectively.3.2. Frequency, uptake and metabolization by M. galloprovincialis
The results showed that neither ﬂuoxetine nor norﬂuoxetine
was detected in un-exposed mussels. On the contrary, as presented
in Fig. 1, in mussels exposed to ﬂuoxetine at 75 ng L1 (nominal
concentration), ﬂuoxetine, and norﬂuoxetine were detected and
concentrations increased with the time of exposure. After 3 days of
exposure, ﬂuoxetine was detected in 70% of the samples with a
mean of 2.53 ng g1 d.w., while norﬂuoxetinewas found in only one
sample (10%), at 3.06 ng g1 d.w. At day 7, the frequency of
detection in the samples increased to 80 and 50%, for ﬂuoxetine and
norﬂuoxetine, respectively, as well as their mean levels, 4.43 and
2.85 ng g1 d.w., respectively. By day 15, the mean concentration of
ﬂuoxetine and of norﬂuoxetine was 9.31 and 11.65 ng g1 d.w.,
respectively. Maximum ﬂuoxetine and norﬂuoxetine concentra-
tions of 23.81 and 24.10 ng g1 d.w. were detected in
M. galloprovincialis after 15 days of exposure. The sum of ﬂuoxetine
and norﬂuoxetine in mussel tissues reached a maximum concen-
tration of 47.91 ng g1 d.w.
Statistical analysis, using KruskaleWallis test with Dunns post-
test (setting p < 0.05), showed signiﬁcant differences between days
3 and 15 (p ¼ 0.0021) for ﬂuoxetine, and between days 7 and 15
(p ¼ 0.0041) and between days 3 and 15 (p < 0.0001), for
norﬂuoxetine.
Although the absence of ﬂuoxetine or norﬂuoxetine was not
veriﬁed one could assume that, the seawater used did not
contribute for the bioconcentration of ﬂuoxetine nor norﬂuoxetine
in mussels since neither one was detected in un-exposed (control)
mussels. On the other hand, regarding the possible transformation
of the ﬂuoxetine added to the tanks into norﬂuoxetine, eventhough
the concentration of norﬂuoxetine was not conﬁrmed in the
aqueous phase, according to Kwon and Armbrust (2006), who
conducted a study on the fate and the persistence of ﬂuoxetine
under laboratory conditions, ﬂuoxetine is recalcitrant to photolysis,
hydrolysis, and microbial degradation. In the above-mentioned
study, samples were placed in the dark and/or in a growth cham-
ber ﬁtted with ﬂuorescent lamps simulating the ultraviolet output
of sunlight. Over a period of 30 days (note that our study was
conducted during a lower period of 15 days and that the water was
changed every 48 h and ﬂuoxetine concentration re-established)
ﬂuoxetine was hydrolytically and photolytically stable in all
aqueous solutions used (pH 5, 7, and 9) (note that our study was
conducted at a pH of 8) except synthetic humic water (pH 7). Based
on results of ready-biodegradability investigations, ﬂuoxetine
would not be expected to rapidly biodegrade in wastewater treat-
ment plants. A photoproduct, norﬂuoxetine, was detected only in a(%) RSD within-day (%) RSD between-day (%)
25 ng g1 50 ng g1 5 ng g1 25 ng g1 50 ng g1 5 ng g1 25 ng g1 50 ng g1
91.31 99.76 0.16 0.77 0.71 10.06 0.84 0.55
95.39 99.35 2.35 0.05 1.94 1.46 1.19 0.27
Fig. 1. Fluoxetine (A), norﬂuoxetine (B) and their sum (C) accumulated in
M. galloprovincialis in different exposure days. Values are expressed as the mean ± SD
(n ¼ 10) (ng g1 d.w.). Different letters express signiﬁcant differences (p < 0.05).
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ﬂuoxetine formed by demethylation. Moreover, Mendez-Arriaga
et al. (2011), also stated that photolysis of ﬂuoxetine is remark-
able only under alkaline pH.
A rapid uptake of ﬂuoxetine via waterborne exposure across the
gills of mussels, presumably through feeding and respiratory ac-
tivities, probably took place (Franzellitti et al., 2014). Detectable
levels of ﬂuoxetine were also observed by Franzellitti et al. (2014) in
mussels whole tissues (digestive gland, gills and mantle/gonads)exposed for 7 days to 30 and 300 ng L1 of this SSRI. The rank order
of ﬂuoxetine accumulation in tissues was: digestive
gland  gills > mantle/gonads, varying between 8.43 and
25.01 ng g1 w.w. and between 57.10 and 192.89 ng g1 w.w., for the
lower and higher exposure levels, respectively.
Bringolf et al. (2010) also observed that, only after 14 days of
exposure, caged mussels at stream sites near a municipal WWTP
efﬂuent discharge accumulated substantial quantities of ﬂuoxetine
in their tissues. Fluoxetine concentrations measured in mussels
from a WWTP efﬂuent channel (maximum of 119 ng L1) and from
downstream sites, were of 79.1 and 9.8 ng g1 w.w., respectively.
Taking into account that the water content of raw mussels is
about 82.5% (INSA, 2015), both of the above-mentioned studies
report levels higher than the ones of the present work, nonetheless,
in these studies, measurements of ﬂuoxetine were performed in
mussels depurated for only 3 days (Franzellitti et al., 2014) or not
depurated at all (Bringolf et al., 2010).
Comparison between species, for instance mussels and ﬁsh,
might be hampered by distinct lipid contents that may contribute
for different accumulation patterns of the lipophilic ﬂuoxetine
(Gust et al., 2009). Even so, the ﬁrst data that regarded ﬂuoxetine
and norﬂuoxetine accumulation in brain, liver, and muscle of
different ﬁsh species of efﬂuent-dominated ecosystems was re-
ported by Brooks et al. (2005). Among the three ﬁsh species
examined, average norﬂuoxetine levels were higher than ﬂuoxe-
tine. In decreasing order, norﬂuoxetine was found at 10.27 ng g1 in
liver, at 8.86 ng g1 in brain, and at 1.07 ng g1 in muscle tissues,
whereas ﬂuoxetine was present at 1.34, 1.58, and 0.11 ng g1,
respectively. These observations were also made by other re-
searchers (Lajeunesse et al., 2011; Metcalfe et al., 2010; Ramirez
et al., 2009, 2007; Schultz et al., 2010). Similarly, Gelsleichter and
Szabo (2013) could only measure norﬂuoxetine, not ﬂuoxetine, at
4.08 ng mL1, in the plasma of bull sharks (Carcharhinus leucas)
inhabiting a wastewater-impacted river. In contrast, Chu and
Metcalfe (2007) reported lower concentrations of norﬂuoxetine
(0.27 ng g1 w.w.) than of ﬂuoxetine (0.37 ng g1 w.w.) in ﬁsh
tissues collected from an harbour heavily impacted by discharges
from municipal WWTPs.
In our study, norﬂuoxetine levels were lower than those of
ﬂuoxetine during the ﬁrst week of exposure. However, by the end of
the exposure period levels were slightly higher than those of
ﬂuoxetine. The ratio of norﬂuoxetine and ﬂuoxetine were 0.12, 0.64
and 1.25 at 3, 7 and 15 days of exposure, respectively. These results
suggest that the ﬂuoxetine accumulated in mussel tissues is likely
to be metabolised into norﬂuoxetine with the increase of ﬂuoxetine
accumulation and with the time of exposure.
As far as we know this is the ﬁrst study that suggests the
metabolization of ﬂuoxetine in mussels, therefore comparisonwith
other studies is difﬁcult. Moreover, depending on the species, cy-
tochrome P-450 dependent monooxygenase biotransforms, at
different rates, ﬂuoxetine into norﬂuoxetine (Gust et al., 2009).
Indeed, in freshwater ﬁsh Japanese medaka (Oryzias latipes)
exposed to ﬂuoxetine (640 ng L1) for 7 days, norﬂuoxetine con-
centrations were below those measured for ﬂuoxetine until day 7,
when the average concentration of the metabolite
(64.3 ± 8.7 ng g1 w.w.) was higher than that of for ﬂuoxetine
(40.8 ± 5.0 ng g1 w.w.) (Paterson and Metcalfe, 2008). A ratio of
norﬂuoxetine to ﬂuoxetine of approximately 2 was reported. On the
other hand, Nakamura et al. (2008) found ratios of norﬂuoxetine
and ﬂuoxetine of 5.3 and 1.1 in the whole body of the ﬁsh Japanese
medaka when exposed to 30 mg L1 and 300 mg L1, respectively, of
this SSRI, for 30 days.
One should also note that, since ﬂuoxetine is a weak base (pKa
10.05), and the neutral form dominates at pH values near its pKa
and the cationic form dominates at lower pH values, accumulation
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2010; Ramirez et al., 2009). In fact, in vitro, the ratio of non-
ionized species increased for ﬂuoxetine by a factor of 100 when
increasing the pH from 7 to 9. This could be also observed in ﬁsh
where the accumulation of ﬂuoxetine and its major metabolite
norﬂuoxetine was multiplied while pH was elevated (Nakamura
et al., 2008).
3.3. Fluoxetine BCFs and norﬂuoxetine pseudo-BCFs
A bioconcentration factor (BCF) is calculated as the ratio be-
tween the concentration of the compound of interest in the biota
and that in the surrounding media (Zenker et al., 2014) and is
commonly used in risk assessment analysis.
The BCF was calculated based on accumulation of ﬂuoxetine in
each mussel and the nominal water concentration (75 ng L1)
(Nakamura et al., 2008). Fluoxetine was detected in 70% of the
mussels only after 3 days of exposure. The BCFs calculated were
34, 59, and 124, at 3, 7 and 15 days, respectively, which corre-
sponds to a log BCF between 1.5 and 2.1. Moreover a ﬁrst order
kinetic model was applied to the data and revealed that the steady
state would only be reached after 52 days of exposure and that
kinetic BCF (calculated as the ratio of the uptake and elimination
rate constants) (Mackay and Fraser, 2000) was 129. Paterson and
Metcalfe (2008) also estimated a kinetic BCF of 80 in the Japa-
nese medaka exposed to a nominal ﬂuoxetine concentration of
640 ng L1. Fluoxetine octanol-water partition coefﬁcient (Log
Kow) ranges from 1.25 to 4.3 at pH ranging from 2 to 11 (Brooks
et al., 2003). Estimating from these data, the log Kow for pH 8 is
2.4, and BCFs were much lower than those obtained in this study
suggesting, as pointed out by Paterson and Metcalfe (2008), the
limited utility of log Kow for estimating the ﬂuoxetine BCF in
mussels.
Norﬂuoxetine, like some other SSRI metabolites, is less polar
than its parent compound being therefore more prone to accu-
mulation than ﬂuoxetine, and capable of eliciting the same or even
worse biological effects (Gelsleichter and Szabo, 2013). The pseudo-
BCF value for norﬂuoxetine (calculated based on the concentration
of norﬂuoxetine detected in each mussel and the nominal water
concentration of ﬂuoxetine (75 ng L1) in water (Nakamura et al.,
2008)) was of 4, 38 and 155, for days 3, 7 and 15, respectively.
The pseudo-BCF value at day 15 was higher than the BCF value of
ﬂuoxetine (log BCF ¼ 2.2). The kinetic model applied indicated that
the elimination rate was much longer than that of ﬂuoxetine. This
suggests the activemetabolism of ﬂuoxetinemay have implications
on mussel's health.
Considering both forms together, the pseudo-BCFs were 38, 97,
and 399 for 3, 7 and 15 days respectively. The BCFs of ﬂuoxetine
were <1500 which suggest low accumulation potential but it does
not rule out the capacity of ﬂuoxetine to induce biological effects as
those observed by Gonzalez-Rey and Bebianno (2013). To our
knowledge, this is the ﬁrst BCF reported for the sum of ﬂuoxetine
and its metabolite in mussels.
Recently, Franzellitti et al. (2014) reported higher BCFs values for
ﬂuoxetine ranging from 200 to 800 in M. galloprovincialis, after a 7
day treatment with 30 and 300 ng L1. Paterson and Metcalfe
(2008) also reported higher BCF and pseudo-BCF values for ﬂuox-
etine and norﬂuoxetine, after 7 day exposure, of 74 and 117,
respectively, when Japanese medaka was exposed at a nominal
concentration of ﬂuoxetine of 640 ng L1. Nonetheless, our results
are consistent with the pseudo-BCFs of 170 calculated for the Jap-
anese medaka calculated by Nakamura et al. (2008) for exposures
at the same pH of the present study (pH 8.1). A lower norﬂuoxetine
pseudo-BCF, of approximately 60, was calculated for fathead min-
nows (Pimephales promelas) caged for 14 days in the Grand Riverdownstream of a WWTP by Metcalfe et al. (2010). Nakamura et al.
(2008) also determined the distribution coefﬁcients in 1-octanol/
water (Dow) and liposome/water (Dlip-wat) of ﬂuoxetine at a range
of pH between 7 and 9 (4.6 ± 0.6  102 and 2.4 ± 0.8  104
respectively at pH 8) and concluded that Dlip-wat was less variable
with pH than Dow and therefore more likely to be used to predict
ﬂuoxetine accumulation potential while no changes were observed
for norﬂuoxetine.
3.4. Links between biological effects in mussels M. galloprovincialis
and BCFs ratios
The presence of ﬂuoxetine has been previously associated to
promote the enhancement of lipid peroxidation (LPO) in mussels'
digestive gland (5-fold higher than control), as well as a small in-
crease of antioxidant enzyme catalase and phase II glutathione-S-
transferase activities after 15 days of exposure to the same ﬂuox-
etine concentration (75 ng L1) (Gonzalez-Rey and Bebianno, 2013).
Previously to that time period, the results concerning the antioxi-
dant system response and associated damagewere not signiﬁcantly
different from the control (Gonzalez-Rey and Bebianno, 2013). As
mentioned above, the presence of norﬂuoxetine is considered to be
potentially more damaging than ﬂuoxetine alone for biota
(Gelsleichter and Szabo, 2013). The observed damage and antioxi-
dant response increased in ﬂuoxetine-exposed mussels after 15
days (Gonzalez-Rey and Bebianno, 2013) which coincides with the
time framewhen the concentrations of norﬂuoxetine surpass those
of the parental compound. This suggests that these effects may be
due to the biotransformation of ﬂuoxetine to norﬂuoxetine
potentiating its effects on non-target organisms.
4. Conclusions
Overall, the data suggests that the ﬂuoxetine accumulated in the
marine mussels M. galloprovincialis is metabolized into nor-
ﬂuoxetine. Both accumulation and metabolization increased along
the exposure period with signiﬁcant differences between days 3
and 15 for ﬂuoxetine, and between days 7 and 15 and days 3 and 15,
for norﬂuoxetine. The BCFs calculated were 34, 59, and 124, at 3, 7
and 15 days, respectively, and the pseudo-BCF values for nor-
ﬂuoxetine were 4, 38 and 155 for 3, 7 and 15 days respectively. The
steady state would only be reached after 52 days of exposure and
the kinetic BCF of ﬂuoxetine was of 129. Since norﬂuoxetine is more
active than ﬂuoxetine, and its pseudo-BCF is higher than ﬂuoxetine
BCF, at day 15, presumably this metabolization potentiates the
biological effects on mussels. Considering the toxicity assays
already developed, it is expected that at environmental measured
concentrations, toxicity effects may occur.
Additionally the presence of SSRIs in the aquatic environment is
commonly associated with the impact of municipal wastewater
efﬂuents, where these compounds are generally present as mix-
tures in surfacewaters. Therefore, further studies should be focused
on monitoring the uptake of the mixture of these antidepressants
by mussels, as expected, good indicators of the presence of these
pharmaceuticals.
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